Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: Prospective cohort study

BMJ (Online)

Volumn 338, Issue 7704, 2009, Pages 1191-1194

  Wood, Evan ^a   Kerr, Thomas ^a   Marshall, Brandon D L ^b   Li, Kathy ^a   Zhang, Ruth ^a   Hogg, Robert S ^a   Harrigan, P Richard ^a   Montaner, Julio S G ^b  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

ADULT; ARTICLE; BLOOD LEVEL; CANADA; COHORT ANALYSIS; COMMUNITY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INTRAVENOUS DRUG ABUSE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SEROCONVERSION; SEXUAL BEHAVIOR; UNSAFE SEX; VIRUS LOAD;

ADULT; BRITISH COLUMBIA; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; MALE; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS; URBAN HEALTH;

EID: 67650035326     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b1649     Document Type: Article

References (31)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
2. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337:725-33.
3. Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 2000;287:650-4.
4. Velasco-Hernandez JX, Gershengorn HB, Blower SM. Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis 2002;2:487-93.
5. Cohen MS, Gay C, Kashuba AD, Blower S, Paxton L. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007;146:591-601.
6. Montaner JS, Hogg R, Wood E, Kerr T, Tyndall M, Levy AR, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006;368:531-6.
7. HIV vaccine failure prompts Merck to halt trial. Nature 2007;449:390.
8. Cohen J. AIDS research. Microbicide fails to protect against HIV. Science 2008;319:1026-7.
9. Steinbrook R. The AIDS epidemic - a progress report from Mexico City. N Engl J Med 2008;359:885-7.
10. World Health Organization. Consensus statement: addressing knowledge gaps in the public health approach to delivering antiretroviral therapy and care. www.iasociety.org/Web/ WebContent/File/Consensus%20Statement%2030-07- 08.pdf.
11. Aceijas C, Oppenheimer E, Stimson GV, Ashcroft RE,Matic S, Hickman M. Antiretroviral treatment for injecting drug users in developing and transitional countries 1 year before the end of the "Treating 3million by 2005. Making it happen. TheWHO strategy" ("3 by 5"). Addiction 2006;101:1246-53.
12. Marseille E, Hofmann PB, Kahn JG. HIV prevention before HAART in sub-Saharan Africa. Lancet 2002;359:1851-6.
13. Kerr T, Tyndall M, Li K, Montaner JS, Wood E. Safer injection facility use and syringe sharing in injection drug users. Lancet 2005;366:316-8.
14. Wood E, Lloyd-Smith E, Li K, Strathdee SA, Small W, Tyndall MW, et al. Frequent needle exchange use and HIV incidence in Vancouver, Canada. Am J Med 2007;120:172-9.
15. Strathdee SA, Palepu A, Cornelisse PG, Yip B, O'Shaughnessy MV, Montaner JS, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998;280:547-9.
16. Wood E, Hogg RS, Bonner S, Kerr T, Li K, Palepu A, et al. Staging for antiretroviral therapy among HIV-infected drug users. JAMA 2004;292:1175-7.
17. Dunn J, Ferri CP. Epidemiological methods for research with drug misusers: review of methods for studying prevalence and morbidity. Rev Saude Publica 1999;33:206-15.
18. Lopes CS, Rodrigues LC, Sichieri R. The lack of selection bias in a snowball sampled case-control study on drug abuse. Int J Epidemiol 1996;25:1267-70.
19. Strathdee SA, Patrick DM, Currie SL, Cornelisse PG, Rekart ML, Montaner JS, et al. Needle exchange is not enough: lessons fromthe Vancouver injecting drug use study. AIDS 1997;11:F59-65.
20. Collett, D. Modelling survival data in medical research. NewYork: Chapman & Hall, 1994.
21. Loughlin A, Metsch L, Gardner L, Anderson-Mahoney P, Barrigan M, Strathdee S. Provider barriers to prescribing HAART to medically-eligible HIV-infected drug users. AIDS Care 2004;16:485-500.
22. Wood E, Hogg RS, Harrigan PR, Montaner JS. When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients. Lancet Infect Dis 2005;5:407-14.
23. Wood E, Hogg RS, Yip B, Moore D, Harrigan PR, Montaner JS. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or =200 cells/microl. AIDS 2006;20:1117-23.
24. Cu-Uvin S, Caliendo AM, Reinert S, Chang A, Juliano-Remollino C, Flanigan TP, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 2000;14:415-21.
25. Lampinen TM, CritchlowCW, Kuypers JM, Hurt CS,Nelson PJ, Hawes SE, et al. Association of antiretroviral therapy with detection of HIV-1 RNA and DNA in the anorectal mucosa of homosexual men. AIDS 2000;14:F69-75.
26. Vernazza PL, Gilliam BL, Flepp M, Dyer JR, Frank AC, Fiscus SA, et al. Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS 1997;11:1249-54.
27. Fang CT, Hsu HM, Twu SJ, Chen MY, Chang YY, Hwang JS, et al. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis 2004;190:879-85.
28. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000;342:921-9.
29. Martinez-Picado J, DePasquale MP, Kartsonis N, Hanna GJ, Wong J, Finzi D, et al. Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc Natl Acad Sci U S A 2000;97:10948-53.
30. Gallego O, de Mendoza C, Perez-Elias MJ, Guardiola JM, Pedreira J, Dalmau D, et al. Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. AIDS 2001;15(13):1701-6.
31. Tyndall MW, Craib KJ, Currie S, Li K, O'Shaughnessy MV, Schechter MT. Impact of HIV infection on mortality in a cohort of injection drug users. J Acquir Immune Defic Syndr 2001;28:351-7.